Ken Griffin Biocryst Pharmaceuticals Inc Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 55,000 shares of BCRX stock, worth $410,850. This represents 0.0% of its overall portfolio holdings.
Number of Shares
55,000
Previous 468,300
88.26%
Holding current value
$410,850
Previous $2.81 Million
90.05%
% of portfolio
0.0%
Previous 0.0%
Shares
26 transactions
Others Institutions Holding BCRX
# of Institutions
254Shares Held
181MCall Options Held
839KPut Options Held
816K-
Black Rock Inc. New York, NY18.4MShares$138 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA17.7MShares$132 Million0.0% of portfolio
-
State Street Corp Boston, MA17.5MShares$131 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY13.1MShares$97.5 Million0.8% of portfolio
-
Baker Bros. Advisors LP New York, NY10.1MShares$75.6 Million0.65% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.39B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...